Yes

This debate will examine the evolving role of oral selective estrogen receptor degraders (SERDs) in breast cancer and address the question of whether these agents are truly interchangeable. Compare differences in mechanism of action, clinical efficacy, resistance profiles, and safety across available and emerging oral SERDs. Speakers will highlight implications for patient selection and sequencing in hormone receptor-positive disease and provide expert insight into how nuanced differences among oral SERDs may influence real-world treatment decisions. Faculty will review shared mechanisms of action, class-wide efficacy data, and common safety profiles across available, largely comparable therapeutic agents. The discussion will address whether differences among oral SERDs translate into meaningful distinctions in clinical practice, and participants will gain insight into the rationale for viewing oral SERDs as a broadly similar therapeutic class in hormone receptor-positive breast cancer.